Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APLT

APLT - Applied Therapeutics Inc Stock Price, Fair Value and News

5.13USD-0.18 (-3.39%)Delayed as of 21 Feb 2024, 02:03 pm ET
Watchlist

Market Summary

USD5.13-0.18
Delayedas of 21 Feb 2024, 02:03 pm
-3.39%

APLT Stock Price

View Fullscreen

APLT RSI Chart

APLT Valuation

Market Cap

410.1M

Price/Earnings (Trailing)

-4.25

Price/Sales (Trailing)

5.68

Price/Free Cashflow

-7.59

APLT Price/Sales (Trailing)

APLT Profitability

Return on Equity

-22.99%

Return on Assets

-213.55%

Free Cashflow Yield

-13.18%

APLT Fundamentals

APLT Revenue

APLT Earnings

Earnings (TTM)

-96.5M

Earnings Growth (Yr)

-121.82%

Earnings Growth (Qtr)

-43.25%

Breaking Down APLT Revenue

52 Week Range

0.765.37
(Low)(High)

Last 7 days

93.5%

Last 30 days

115.2%

Last 90 days

170.4%

Trailing 12 Months

422.3%

How does APLT drawdown profile look like?

APLT Financial Health

Current Ratio

0.8

APLT Investor Care

Shares Dilution (1Y)

60.70%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000

Tracking the Latest Insider Buys and Sells of Applied Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 21, 2023
hansard adam
acquired
-
-
400,000
chief commercial officer
Dec 21, 2023
shendelman shoshana
acquired
-
-
1,540,000
president and ceo
Dec 21, 2023
perfetti riccardo
acquired
-
-
450,000
chief medical officer
Dec 01, 2023
kanter stacy j.
bought
65,367
2.1789
30,000
-
Nov 30, 2023
shendelman shoshana
sold
-7,816
1.97
-3,968
president and ceo
Nov 30, 2023
hansard adam
sold
-1,901
1.97
-965
chief commercial officer
Nov 30, 2023
perfetti riccardo
sold
-3,118
1.97
-1,583
chief medical officer
Nov 29, 2023
alexandria real estate equities, inc.
acquired
-
-
575,000
-
Nov 29, 2023
alexandria real estate equities, inc.
sold
-
-
-575,000
-
Nov 20, 2023
funtleyder leslie d.
acquired
-
-
300,000
chief financial officer

1–10 of 50

Which funds bought or sold APLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-35.08
-64,031
441,885
-%
Feb 14, 2024
Alyeska Investment Group, L.P.
reduced
-38.29
-1,783,630
8,725,810
0.06%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
added
226
132,006
170,850
-%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
new
-
83,629
83,629
-%
Feb 14, 2024
ACUTA CAPITAL PARTNERS, LLC
new
-
1,759,080
1,759,080
0.99%
Feb 14, 2024
EAM Investors, LLC
reduced
-53.3
-362,457
612,615
0.11%
Feb 14, 2024
Rock Springs Capital Management LP
added
10.68
984,969
2,998,900
0.07%
Feb 14, 2024
Opaleye Management Inc.
added
22.34
1,436,300
3,659,880
0.97%
Feb 14, 2024
Cubist Systematic Strategies, LLC
added
1,198
185,065
196,300
-%
Feb 14, 2024
VR Adviser, LLC
added
10.46
6,849,000
20,937,500
1.44%

1–10 of 42

Are Funds Buying or Selling APLT?

Are funds buying APLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APLT
No. of Funds

Unveiling Applied Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.99%
7,877,817
SC 13G/A
Feb 14, 2024
armistice capital, llc
0%
0
SC 13G/A
Feb 14, 2024
alyeska investment group, l.p.
9.99%
7,715,197
SC 13G/A
Feb 14, 2024
perceptive advisors llc
5.9%
4,580,249
SC 13G/A
Feb 14, 2024
orbimed advisors llc
0.0%
0
SC 13G/A
Feb 14, 2024
alexandria real estate equities, inc.
15.4%
12,859,054
SC 13G/A
Feb 13, 2024
vestal point capital, lp
5.4%
4,155,000
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 06, 2024
franklin resources inc
9.99%
7,793,912
SC 13G/A
Dec 11, 2023
franklin resources inc
10.2%
7,870,697
SC 13G/A

Recent SEC filings of Applied Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 15, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Applied Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Applied Therapeutics Inc News

Latest updates
InvestorsObserver27 hours ago
MarketBeat17 Feb 202405:37 pm
Seeking Alpha16 Feb 202405:56 pm
InvestorPlace05 Jan 202408:00 am

Applied Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q1
Revenue---11.00
Operating Expenses-9.8%15.0017.0022.00
  S&GA Expenses-11.0%5.005.006.00
  R&D Expenses-9.2%11.0012.0016.00
Net Income-43.3%-42.37-29.58-10.14
Net Income Margin100.0%--3.44*-1.63*
Free Cashflow10.5%-14.73-16.45-6.99
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets3.5%45.0044.0030.0038.0057.0078.0065.0090.0011913715610512515116648.0037.0047.0017.0020.0016.00
  Current Assets3.9%44.0043.0029.0037.0056.0077.0064.0088.0011713515410312314916446.0037.0047.0017.0020.00-
    Cash Equivalents5.3%38.0036.0023.0017.0040.0056.0038.0054.0070.0078.0084.0057.0049.0010193.0019.0013.0041.0015.0019.004.00
Liabilities17.2%56.0048.0034.0034.0047.0052.0023.0027.0032.0025.0021.0023.0022.0020.0010.0016.007.007.006.004.004.00
  Current Liabilities17.6%56.0047.0033.0033.0047.0052.0022.0026.0031.0023.0020.0021.0021.0019.008.0014.007.007.006.004.00-
Shareholder's Equity9.3%4203843554.0010.0026.0042.0063.0087.0011213582.0010313015633.0031.0040.002.002.001.00
  Retained Earnings-10.9%-430-388-358-348-334-315-289-266-239-210-184-160-137-107-79.14-66.77-49.14-38.42-29.99-21.26-
  Additional Paid-In Capital9.3%42038435535334434133132932632332024324023723599.0080.0078.002.002.00-
Shares Outstanding24.2%77.0062.0048.0048.0034.0027.0026.0026.0026.0025.0024.0022.00---------
Float------28.00---393---659---68.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations10.5%-14,726-16,452-6,990-15,893-19,390-18,400-24,410-26,942-15,665-25,908-22,213-22,750-20,693-15,911-18,855-12,407-7,839-9,059-7,002-5,869-2,020
  Share Based Compensation-0.4%1,8361,8432,0551,5573,2972,2312,0772,8492,6452,7022,9812,5552,4031,7371,3311,3481,2193,27932592.0078.00
Cashflow From Investing---13,872-6,9055,0215,5299,52511,8078,51816,780-24,67228,444-30,24624,044-41,711------
Cashflow From Financing-43.2%16,56729,151-622-933-97130,385-789-1,184-1,0803,49573,4863,093-1,236218134,21918,320-29435,4492,94021,05628.00

APLT Income Statement

2023-09-30
Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
REVENUE:    
License Revenue  $ 10,660 
Revenue from Contract with Customer, Product and Service  us-gaap:LicenseMember 
Total Revenue  $ 10,660 
OPERATING EXPENSES:    
Research and development$ 10,785$ 13,11638,602$ 43,542
General and administrative4,7106,24015,58520,436
Total operating expenses15,49519,35654,18763,978
LOSS FROM OPERATIONS(15,495)(19,356)(43,527)(63,978)
OTHER INCOME (EXPENSE), NET:    
Interest income3922271,020414
Change in fair value of warrant liabilities(27,277)36(39,611)(4,321)
Other income (expense):10(8)34(194)
Total other income (expense), net(26,875)255(38,557)(4,101)
Net loss(42,370)(19,101)(82,084)(68,079)
Net loss attributable to common stockholders-basic(42,370)(19,101)(82,084)(68,079)
Net loss attributable to common stockholders-diluted$ (42,370)$ (19,101)$ (82,084)$ (68,079)
Net loss per share attributable to common stockholders-basic (in dollars per share)$ (0.47)$ (0.40)$ (1.09)$ (2.02)
Net loss per share attributable to common stockholders-diluted (in dollars per share)$ (0.47)$ (0.40)$ (1.09)$ (2.02)
Weighted-average common stock outstanding-basic (in shares)90,669,96948,000,18375,482,23433,785,386
Weighted-average common stock outstanding-diluted (in shares)90,669,96948,000,18375,482,23433,785,386

APLT Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 37,457$ 16,657
Investments 13,923
Prepaid expenses and other current assets7,0316,728
Total current assets44,48837,308
Operating lease right-of-use asset510857
Security deposits and leasehold improvements197198
TOTAL ASSETS45,19538,363
CURRENT LIABILITIES:  
Current portion of operating lease liabilities491477
Accounts payable6,0054,534
Accrued expenses and other current liabilities12,24514,756
Warrant liabilities36,76313,657
Total current liabilities55,50433,424
NONCURRENT LIABILITIES:  
Noncurrent portion of operating lease liabilities44414
Clinical holdback - long-term portion691464
Total noncurrent liabilities735878
Total liabilities56,23934,302
STOCKHOLDERS' (DEFICIT)/EQUITY:  
Common stock, $0.0001 par value; 200,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 77,133,516 shares issued and outstanding as of September 30, 2023 and 48,063,358 shares issued and outstanding as of December 31, 202275
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022
Additional paid-in capital419,856352,828
Accumulated other comprehensive gain 51
Accumulated deficit(430,907)(348,823)
Total stockholders' (deficit)/equity(11,044)4,061
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY$ 45,195$ 38,363
APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEwww.appliedtherapeutics.com
 EMPLOYEES22

Applied Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Applied Therapeutics Inc? What does APLT stand for in stocks?

APLT is the stock ticker symbol of Applied Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Therapeutics Inc (APLT)?

As of Tue Feb 20 2024, market cap of Applied Therapeutics Inc is 410.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers. The fair value of Applied Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APLT is over valued or under valued. Whether Applied Therapeutics Inc is cheap or expensive depends on the assumptions which impact Applied Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLT.

What is Applied Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, APLT's PE ratio (Price to Earnings) is -4.25 and Price to Sales (PS) ratio is 5.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLT PE ratio will change depending on the future growth rate expectations of investors.